Lexaria Bioscience Corp Stock price
Is Lexaria Bioscience Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Lexaria Bioscience Corp Stock Analysis
Analyst Opinions
7 Analysts have issued a Lexaria Bioscience Corp forecast:
Analyst Opinions
7 Analysts have issued a Lexaria Bioscience Corp forecast:
Don't miss a Thing! We will send you all news about Lexaria Bioscience Corp directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lexaria Bioscience Corp Stock News
Company Profile
Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
| Head office | United States |
| CEO | Mr. Christopher |
| Employees | 7 |
| Founded | 2004 |
| Website | www.lexariabioscience.com |


